-25% en todo – hasta el 31 de octubreEnvío gratis en pedidos desde $99
SwissChems

Uso del producto: Este producto está destinado exclusivamente a la investigación.

Toda la información de los productos de este sitio web tiene fines exclusivamente educativos. Cualquier forma de introducción en el cuerpo de personas o animales está estrictamente prohibida por la ley. Este producto solo debe ser manipulado por profesionales autorizados y cualificados. No es un medicamento, alimento ni cosmético y no debe etiquetarse, utilizarse ni presentarse como tal.

Raloxifene (20mg/capsule), 60 Capsules

Ref.:RALXFN-60
Cantidad
El precio original era: $99.95.El precio actual es: $74.96.
La misma fórmula de confianza. Nuevo diseño.

Durante el cambio de envase, puedes recibir productos con la etiqueta anterior o con la nueva. La formulación, la pureza y la calidad siguen siendo exactamente las mismas, según nuestros estándares.

Métodos de pago aceptados
  • Tarjeta de crédito
  • Transferencia bancaria (SEPA inmediata)
  • Transferencia bancaria (ACH)
  • Wise
  • Revolut
  • Zelle
  • Remitly
  • Western Union
  • Chime
  • Otros

-25% en todo – hasta el 31 de octubre
25% sobre los precios habituales, en sustitución de otras ofertas. Acumulable solo con el descuento crypto.

Envío

Envío en el día para pedidos en EE. UU. realizados antes de las 12:00 EST.

Ver la política de envíos →
Devoluciones

Devoluciones sin complicaciones en 30 días para productos sin abrir.

Ver la política de devoluciones →
Analizado en laboratorio

Cada lote se analiza para comprobar su pureza, potencia y calidad.

Ver resultados de laboratorio →
Atención al cliente

¿Tienes alguna pregunta? Escríbenos por Telegram.

Abrir el chat →

Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits tissue-specific agonist and antagonist activity at estrogen receptors (ERs). It interacts with ERα and ERβ, influencing gene transcription and receptor-mediated signaling pathways.

This compound undergoes hepatic metabolism primarily via glucuronidation, producing inactive glucuronide conjugates.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

3D Molecular Structure

Drag to rotate · scroll to zoom
Loading 3D structure…
Chemical Formula C28H27NO4S
Synonyms Keoxifene, LY156758
Molar Mass 473.58 g/mol
CAS Number 84449-90-1
PubChem CID 5035
Total Compound Content 5 grams
Shelf Life 36 months
Raloxifene binds competitively to both estrogen receptor subtypes (ERα and ERβ), producing conformational changes in the receptor that recruit different coactivator/corepressor complexes depending on the target tissue — the structural basis of its tissue-selective agonist/antagonist profile. In bone tissue, this conformation favors estrogen-agonist-like signaling, supporting research into its effects on bone mineral density and osteoclast activity. In breast and uterine tissue, the resulting conformation instead favors antagonist activity, a key research contrast point against tamoxifen, which retains partial agonist activity in the endometrium. Research models frequently compare raloxifene against tamoxifen and other SERMs to characterize how ligand structure determines coactivator recruitment and downstream tissue selectivity. Unlike tamoxifen, raloxifene does not require CYP2D6-mediated metabolism to an active form, making it a useful comparative tool in studies of SERM pharmacokinetics and metabolic activation pathways. Independently third-party HPLC-tested; COA available per batch.

Results refer to the tested sample. Check the batch and date in the report.

SC Raloxifene (HPLC)
August 4, 2026
What makes raloxifene's tissue selectivity distinct from tamoxifen's in receptor pharmacology research?

Both compounds bind the estrogen receptor, but the resulting receptor conformation differs in ways that alter coactivator/corepressor recruitment by tissue. Raloxifene's conformation favors antagonist activity in both breast and endometrial tissue, whereas tamoxifen retains partial agonist activity in the endometrium.

This divergence makes head-to-head SERM studies a common approach for mapping how structural differences in ligands translate into tissue-specific transcriptional outcomes.

How is raloxifene used in bone metabolism research models?

Because raloxifene's receptor conformation in bone tissue favors estrogen-agonist-like signaling, it is used in osteoblast/osteoclast culture models and in vivo bone density studies to examine estrogen-receptor-mediated effects on bone turnover, independent of the antagonist activity it shows in reproductive tissue.

What distinguishes raloxifene's metabolic pathway from other SERMs in pharmacokinetic research?

Raloxifene undergoes extensive glucuronidation rather than requiring CYP2D6-mediated bioactivation, unlike tamoxifen, which depends on CYP2D6 conversion to its active metabolite endoxifen. This makes raloxifene a useful comparator in research examining how metabolic activation requirements affect SERM activity and inter-individual variability tied to CYP2D6 polymorphisms.